Evidence from landmark clinical trials consistently demonstrates the kidney-protective effects of ACE inhibitors and ARBs in patients with CKD and albuminuria, both with and without diabetes (62, 63, 65, 66). The gene discussed is ACE; the disease is diabetes mellitus.